suma/necrosis

BACKGROUND OF THE INVENTION Inflammation is the body's defense reaction to injuries such as those caused by mechanical damage, infection or antigenic stimulation. An inflammatory reaction may be expressed pathologically when inflammation is induced by an inappropriate stimulus such as an

BACKGROUND OF THE INVENTION 1. Technical Field of the Invention This invention relates generally to cytoenzymology, and more particularly to methods and reagents used in cytoenzymology. 2. Discussion of the Background Art Apoptosis, or programmed cell death, is a process that involves the activation

FIELD OF THE DISCLOSURE This disclosure relates to the use of Eleutherococcus senticosus maxim extract to inhibit tumor necrosis factor (TNF) in subjects, including humans, animals and cell lines thereof, and to treat disorders mediated by TNF in subjects. BACKGROUND It is becoming increasingly

FIELD OF THE INVENTION The present invention relates to the design and composition of an implant that is used as a growth factor depot to treat avascular necrosis (AVN). More particularly, the depot is in the shape of a small cylinder (straight or curved) or sphere that can be delivered into

FIELD OF THE INVENTION The present invention provides novel polynucleotides encoding Drosophila DmTNF polypeptides, fragments and homologs thereof. The present invention also is directed to novel polynucleotides encoding two Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments and

FIELD OF THE INVENTION The present invention provides novel polynucleotides encoding Drosophila DmTNF polypeptides, fragments and homologs thereof. The present invention also is directed to novel polynucleotides encoding two Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments and

FIELD OF THE INVENTION The invention relates to chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. The invention also relates to methods of synthesizing

FIELD OF THE INVENTION The invention relates to chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. The invention also relates to methods of synthesizing

FIELD OF THE INVENTION The invention relates to chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. The invention also relates to methods of synthesizing

REFERENCE TO RELATED APPLICATIONS Related applications U.S. Ser. No. 13/131,231, .sctn.371(c) Date Feb. 2, 2012, PCT/US2009/065755, filed Nov. 24, 2009, and U.S. 61/117,917, filed Nov. 25, 2008 are herein incorporated by reference in their entireties. REFERENCE TO SEQUENCE LISTING SUBMITTED

REFERENCE TO A SEQUENCE LISTING SUBMITTED ELECTRONICALLY VIA EFS-WEB The content of the electronically submitted sequence listing (Name: sequencelisting.ascii.txt, Size: 115,276 bytes; and Date of Creation: May 25, 2011) is herein incorporated by reference in its entirety. BACKGROUND OF THE

FIELD OF THE INVENTION The present invention relates to a surgical adjuvant composition that provides for reduced tissue and cellular necrosis and/or apoptosis. The composition is particularly useful, for example, for use in arthroscopic surgical procedures and other minimally invasive endoscopic

FIELD OF THE INVENTION The present invention relates to a surgical adjuvant composition that provides for reduced tissue and cellular necrosis and/or apoptosis. The composition is particularly useful, for example, for use in arthroscopic surgical procedures and other minimally invasive endoscopic

BACKGROUND OF THE INVENTION The present invention relates to the treatment of cancer with a parenteral nutritional supplement, particularly a supplement having a specific class of structured lipids as its primary fat source. Surprisingly, the supplement containing these structured lipids, when used

BACKGROUND OF THE INVENTION Compounds which have the property of inhibiting the action of metalloproteinases involved in connective tissue breakdown such as collagenase, stromelysin and gelatinase (known as "matrix metalloproteinases", and herein referred to as MMPs) are thought to be potentially